tag:blogger.com,1999:blog-4859999927943629116.post6141671752528750067..comments2008-09-09T07:31:36.399-07:00DNAmitenoreply@blogger.comBlogger1125tag:blogger.com,1999:blog-4859999927943629116.post-57658774487394259822008-09-09T07:31:00.000-07:002008-09-09T07:31:00.000-07:00Webinar Title: Analysis of Oligonucleotides as Biotherapeutics<BR/><BR/>Date: October 2, 2008<BR/><BR/>Time: 1:00-2:00 EDT<BR/><BR/>Web Address: www.genengnews.com/oligos<BR/><BR/>Contact: Joan Boyce at jboyce@genengnews.com <BR/><BR/>Description:<BR/><BR/>Interest in therapeutic oligos has created demand for methods and instruments for analyzing these molecular classes. This webinar will present the latest techniques for identifying, characterizing, and quantifying important classes of oligonucleotide drugs including antisense phosphorothioates, RNAi agents, oligonucleotide aptamers, and PEGylated oligos.<BR/><BR/>Key learning points for this webinar: <BR/><BR/>§ The capabilities and limitations of oligonucleotide analytic platforms <BR/><BR/>§ How to transfer an analytical method from bench to development and production <BR/><BR/>§ Analyzing oligonucleotides in complex biological samples <BR/><BR/>§ Advances in HPLC and LC/MS techniques that can shorten analysis times <BR/><BR/>§ Regulatory and validation aspects of oligonucleotide analysis <BR/><BR/>Your hosts for this webinar, Ipsita Roymoulik, Ph.D. (Avecia Biotechnology), Yansheng Wu, Ph.D. (Archemix), and Martin Gilar, Ph.D. (Waters Corporation), will detail, through their presentations, specific, unique analytic requirements of oligonucleotides when used as therapeutic molecules. A live Q&amp;A session will follow the presentations, offering you a chance to pose questions to our expert panelists.D.Immaculatehttp://www.blogger.com/profile/08428198772016806793noreply@blogger.com